Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma

• Published in: The oncologist (Dayton, Ohio) Vol. 27; no. 10; pp. 809 - e765
• Main Authors: Riedel, Richard F, Chua, Victoria, Moradkhani, Ania, Krkyan, Natalie, Ahari, Amir, Osada, Atsushi, Chawla, Sant P
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.10.2022
• Subjects: Angiosarcoma; Anthracyclines; Antibiotics, Antineoplastic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Care and treatment; Clinical Trial Results; Complications and side effects; Diagnosis; Epirubicin; Epirubicin - adverse effects; Epirubicin - analogs & derivatives; Health aspects; Hemangiosarcoma - chemically induced; Hemangiosarcoma - drug therapy; Humans; Metastasis; Micelles; Nanoparticles; Neutropenia; Neutropenia - chemically induced; Patient outcomes; Pazopanib; Polymers; Proteins; Thrombocytopenia; Thrombocytopenia - chemically induced; United States; metastatic; angiosarcoma; nanoparticle; epirubicin; NC-6300; soft tissue sarcoma; unresectable
• ISSN: 1083-7159; 1549-490X; 1549-490X
• DOI: 10.1093/oncolo/oyac155

Abstract Background NC-6300 is a novel epirubicin (EPI) drug conjugated polymeric micelle developed using cutting-edge micellar nanoparticle technology. The nanoparticle epirubicin conjugates EPI to a polymer via a pH-sensitive linker which enables the selective EPI release into tumor. Tumor activity was observed in a monotherapy phase Ib trial, where two of two patients with angiosarcoma achieved a partial response. To further explore the activity of NC-6300 in angiosarcoma, an expansion cohort was undertaken. Methods Ten patients with angiosarcoma were enrolled in the expansion cohort. Patients were dosed using the recommended dose of 150 mg/m2 intravenously (IV) once every 3 weeks. The primary endpoint was progression-free survival. Results The most common adverse events (AEs) of any grade, regardless of the causal relationship with NC-6300, were neutropenia (90%), fatigue, and thrombocytopenia (60% each) and nausea (50%). The most common grades 3 and 4 AEs were neutropenia (80%), thrombocytopenia (40%), and anemia and leukopenia (20% each). The median progression-free survival (mPFS) for all subjects was 5.4 months. The mPFS was 3.8 months in subjects with prior anthracycline treatment and 8.2 months in subjects without prior anthracycline treatment. Conclusion NC-6300 was well tolerated, showing promising activity in angiosarcoma patients without prior anthracycline treatment. NC-6300 warrants further investigation (ClinicalTrials.gov Identifier: NCT03168061). To explore the activity of NC-6300 (nanoparticle epirubicin) in angiosarcoma, an expansion cohort was undertaken. The clinical trial results are reported here.